Aviron Message Board - Msg: 5663922

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron

AVIR 3.275

+0.5%

1:01 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mauser96 who wrote (359)	9/3/1998 1:26:00 PM
From: s jones	of 645

RelenzaTM Trial Results to be presented at ICAAC 24 August 1998 Melbourne, Australia -- Biota Holdings Limited today announced that Phase III trial results confirming the efficacy and safety of its influenza treatment RelenzaTM will be presented at the prestigious Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego in September. Results of the RelenzaTM trials - conducted in the Southern Hemisphere during the 1997 winter by Biota's development partner Glaxo Wellcome Australia - confirmed the efficacy and safety of the drug in the treatment of influenza in otherwise healthy and "high risk" adults and adolescents. The results showed RelenzaTM produced a reduction in symptom severity for feverishness, myalgia, weakness, cough and loss of appetite. Patients at a greater risk of complications ("high risk") experienced a 70% reduction in complications due to influenza and a 61% reduction in associated antibiotic use. Those "high risk" patients given RelenzaTM had fewer complications than those given placebo (14% compared to 46%).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next